Trials / Completed

CompletedNCT02321592

GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma

GHSG-AFM13 An Open-label, Randomized, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma

Status: Completed
Phase: Phase 2
Study type: Interventional
Enrollment: 23 (actual)

Sponsor: University of Cologne · Academic / Other
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The study is designed * to demonstrate efficacy of AFM13 with an optimized treatment schedule * to decide whether AFM13 warrants further investigation in a phase III clinical trial

Conditions

Hodgkin Lymphoma

Interventions

Type	Name	Description
DRUG	AFM13

Timeline

Start date: 2015-05-01
Primary completion: 2019-11-01
Completion: 2020-07-01
First posted: 2014-12-22
Last updated: 2020-11-13

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT02321592. Inclusion in this directory is not an endorsement.